0650 Impact of Comorbid Insomnia and Sleep Apnea (COMISA) on Hypoglossal Nerve Stimulator Outcomes

Abstract Introduction Hypoglossal nerve stimulation (HGNS) is an effective therapy for moderate-to-severe obstructive sleep apnea (OSA) in patients intolerant of positive airway pressure. Comorbid insomnia (COMISA) is common and may shape their engagement. Despite reports of improved insomnia symptoms, real-world data suggest reduced adherence and increased support needs. This study evaluated the impact of COMISA on HGNS therapy patterns and outcomes. Methods We conducted a retrospective cohort study of 46 adults with OSA who underwent HGNS implantation at Mayo Clinic Rochester between July 2020 and August 2025. Patients were categorized as OSA alone or COMISA based on pre-implantation data, including documented insomnia diagnosis, insomnia severity index score ≥15, sleep initiation or maintenance complaints, hypnotic or melatonin use, participation in cognitive behavioral therapy for insomnia, or an insomnia care plan within one year prior to activation. We collected HGNS adherence metrics (30-day average nightly use, nightly pauses, percent nights used) at 1, 3, 6, and 12 months; non-visit HGNS-related clinical encounters at 6 and 12 months; and pre- and post-activation AHI from polysomnography or home sleep apnea testing. Longitudinal outcomes were analyzed using mixed-effects models with fixed effects for time and COMISA status and a random intercept for patient. Results The cohort was 54% male and 98% White, with median age 66 years and BMI 31 kg/m2 (24–34). Median pre-implant AHI was 27 (19–40), and 30 patients (65%) had COMISA. Median nightly HGNS use declined from 7.8 to 6.6 hours from 1 to 12 months; mixed-effects modeling confirmed significant decreases over time (p≤0.03). Median nightly therapy pauses increased from 0.1 to 0.5, and median non-visit clinical encounters increased cumulatively from 2.5 at 6 months to 3.0 by 12 months (both p≤0.01). Median AHI reduction was 18.5 (2–27) (p=0.047). There were no statistically significant differences between OSA-alone and COMISA groups in HGNS adherence trajectories, therapy pauses, support needs, or AHI improvement (all p0.05). Conclusion Although HGNS use declined modestly over time, COMISA was not statistically associated with differences in adherence, clinical support needs, or treatment response. Directional trends suggest greater adaptation challenges among patients with COMISA, warranting evaluation in larger prospective studies. Support (if any)